Business
NanoViricides Dual Track Clinical Strategy Explained by a Research Report - Broad-spectrum Antiviral NV-387 At Phase II Clinical Trial Stage for MPox and also for Acute Respiratory Infections of All Viruses
SHELTON, CONNECTICUT / ACCESS Newswire / October 15, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), reports that an analyst research report was published on the Company that explains its dual-track, rapid clinical development strategy ...
About this update from Nanoviricides, Inc.
[{"type":"text","content":"SHELTON, CONNECTICUT / ACCESS Newswire / October 15, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), reports that an analyst research report was published on the Company that explains its dual-track, rapid clinical development strategy for NV-387, going after MPox and also after all respiratory viral infections, that include Influenzas, Coronaviruses, RSV among others. The analyst research report was published by proactive investors news (https://www.proactiveinvestors.com/companies/news/1080303/nanoviricides-dual-track-clinical-development-during-2026-1080303.html/long).","length":605,"tagName":"p"},{"type":"text","content":"The analyst research report summarizes:","length":39,"tagName":"p","attribs":{}},{"type":"text","content":""Nanoviricides (NNVC), a US company, targets the unmet medical need for an effective, broad- spectrum acute oral antiviral therapy with NV-387. NNVC's nano-polymer, micelle technology directly binds and destroys virus particles in the blood preventing them entering and infecting cells; in effect a highly selective, ruthless (but safe) nanomachine.","length":358,"tagName":"p","attribs":{}},{"type":"text","content":"NNVC is now pursuing a dual track strategy for clinical development. The first trial will be against MPox virus, a relative of smallpox. The second is in respiratory viral diseases. NV's lead molecule NV-387 has already completed a Phase 1 study in 2023 showing safety and tolerability.","length":290,"tagName":"p","attribs":{}},{"type":"text","content":"The immediate study, which could start by late CY25 or early in CY26, is for MPox. MPox is an endemic virus related to smallpox so has biodefense applications. Ethics approval for an NV- 387 Phase 2 trial in Congo has already been gained; the next stage is a formal Phase 2 Clinical Trial Application (CTA). A successful African trial could lead to possible development funding from the US biodefense agency (BARDA).","length":416,"tagName":"p","attribs":{}},{"type":"text","content":"The second planned study uses mostly the same CTA as the MPox study but will target respiratory viral diseases. An adaptive "basket-type" trial in India will gather data on NV-387 efficacy against flu, RSV and coronaviruses. This might start in winter 2026 but a later start is possible. This could lead to focused US tri...